leadership

After a 30-year career in pharmaceutical R&D, John Leonard retired from his position as Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie in 2013. Inspired by the opportunity to work with a new therapeutic modality and form a new company, he returned to his life’s passion and joined the Intellia team to direct the research and development effort to make CRISPR/Cas9 technology into a therapeutic reality.
John is among the leading R&D executives who have led breakthrough medicines through their discovery, development and launch into blockbuster drugs. While serving as the Global Head of Pharmaceutical R&D at Abbott Laboratories, John oversaw the development of numerous novel therapeutics. His ground-breaking work with HIV protease inhibitors Norvir® and Kaletra® led to new treatment paradigms for AIDS, his years of work with Humira® made it the all-time top-selling drug worldwide, and he led significant growth of the R&D pipeline at Abbott and Abbvie. John’s teams were twice recognized with the prestigious Prix Galien Award for excellence in pharmaceutical research.
In addition to serving on the Board of Directors of Intellia, John serves on the Board of Directors of QuintilesIMS (NYSE:Q) and Chimerix (Nasdaq:CMRX). He received his M.D. from the Johns Hopkins University School of Medicine and completed his residency in Internal Medicine at Stanford University School of Medicine followed by a fellowship at the National Institutes of Health.

Tom Barnes has led platform-based research and drug discovery teams for over 20 years, and is responsible for extending the reach of Intellia’s CRISPR platform into new areas. A veteran entrepreneur who has helped launch several companies, he has turned creative scientific visions into successful businesses for both startups and established organizations.
Tom has wide-ranging knowledge of biological systems through his work across diverse platforms, including genomics and gene discovery, small molecule drug repositioning, and protein engineering. Previously, as Vice President of Discovery at Eleven Biotherapeutics, Tom led his team in creating a novel chimeric cytokine antagonist, as well as two novel technologies. As Senior Vice President and site head of GeneLogic’s drug repositioning division, he oversaw technology platforms in metabolomics, toxicogenomics, gene expression informatics, and the genetics of drug metabolism and transport.
Tom received his Ph.D. from the University of Cambridge, and completed research fellowships at Harvard Medical School and McGill University.

Graeme Bell is a respected financial executive with an extensive international career in the pharmaceutical industry. As CFO of Intellia, Graeme oversees all financial functions of the company, including planning and analysis, reporting, treasury, tax, accounting and finance. He also is responsible for investor relations, as well as Intellia’s operations and information technologies functions.
Prior to joining Intellia in December 2016, Graeme was the chief financial officer for Anacor Pharmaceuticals, Inc., a publicly traded biotech company, where he led the finance, human resources, business development, IT and facilities functions. He played a key role in Anacor’s $5.2 billion acquisition by Pfizer, Inc. in 2016. Graeme spent the previous two decades holding a range of C-suite and senior-level financial management positions for Merck & Co. in the US and the United Kingdom, including serving as CFO of US operations, where he oversaw a major restructuring of a $20 billion business. He also led Merck’s investor relations department during periods of both growth and challenges.
Graeme is a Fellow of the Institute of Management Accountants and holds an MBA from the University of Durham, United Kingdom.

Nishla Keiser has been working with biotechnology and pharmaceutical companies since 2004, building extensive experience in intellectual property strategy, management, and litigation in technologies ranging from nucleic acid and protein therapeutics, small molecules, formulations, analytics, and medical devices. Prior to joining Intellia, Nishla was an attorney at a leading global intellectual property law firm, where she worked on patent litigation to protect multiple branded pharmaceutical products and strategic IP counseling for biotechnology and pharmaceutical companies ranging from start-up companies to large corporations. At Intellia, Nishla focuses on developing and implementing Intellia’s internal and external IP strategies, as well as general regulatory, compliance, and corporate legal matters for the company. Nishla received her Bachelor of Science degrees in Biology, Chemistry, and Chemical Engineering, a Ph.D. in Bioengineering from the Massachusetts Institute of Technology, and a J.D. from Suffolk University Law School.

Jennifer King is Intellia’s Senior Vice President for Business Development and Alliance Management, where she is responsible for accessing external sources of innovation, establishing the company’s key industry partnerships and overseeing the alliance management activities for these partnerships.
Jennifer brings nearly 20 years of operating experience in the biopharmaceutical industry. Prior to her joining Intellia in June 2015, she held the position of Senior Director of Business Development at Shire Plc, where she was responsible for the sourcing, initial evaluation and negotiation of licensing and acquisition opportunities within the company’s corporate development group. She previously worked in Shire’s rare disease commercial organization as a Global Brand Director for two clinical stage programs. She also served as its Director of New Products, where she was responsible for providing commercial guidance to development and research stage projects, as well as evaluating the commercial attractiveness of business development opportunities. Before joining Shire in 2006, Jennifer held a variety of commercial roles in at Millennium Pharmaceuticals; most notably as the Product Manager for the US launch of VELCADE®.
Jennifer received her B.S. in Biology from the Massachusetts Institute of Technology, earned a Ph.D. in Developmental Biology at the Stanford University School of Medicine, and was awarded her MBA by Northeastern University.

David Morrissey leads the CRISPR/Cas9 delivery technology for in vivo and ex vivo therapeutic programs, including the development and production of RNA, Cas9 protein, and lipid nanoparticles delivery vehicles at Intellia. He also brings more than 20 years of extensive experience in cellular and genetic research and takes part in oversight as a member of the joint steering committees for both Novartis and Regeneron collaborations.
David has a very diverse background in all aspects of biology, including technology development, which includes RNA chemistry, siRNA formats and delivery systems. He has led internal disease area research groups, including Oncology, Infectious Diseases, Cardiovascular, Metabolism, and Respiratory Disease. Most recently, he was the Executive Director at the Novartis Institutes for Biomedical Research, where he established and led its RNAi Therapeutics Unit, and progressed proprietary siRNAs and delivery formulations through NHP efficacy, pharmacokinetic, and toxicology studies. As the Senior Director of Antiviral Therapeutics at Sirna Therapeutics, he played a key role in all aspects of pre-clinical development of antiviral siRNAs, including the development of siRNA chemistry and delivery technology. He also led the team in the selection of the first siRNA-based therapy developed for hepatitis virus infections and oversaw all IND enabling activities.
David has been issued eight U.S. patents, and authored a number of key publications in the RNA interference field. He received his Ph.D. from Wesleyan University and completed his postdoctoral fellowship at Bristol-Myers Squibb.

José Rivera has approximately over 20 years of experience managing complex legal and business issues in the pharmaceutical industry with extensive expertise in navigating the biopharmaceutical intellectual property, regulatory environment, and litigation.
José led Abbott’s global Intellectual Property group, and before that its IP Litigation, Regulatory Legal and Litigation departments. As the head of Abbott’s IP group, José was responsible for managing all aspects of the company’s intellectual property issues worldwide, including prosecution, acquisition, valuation, defense and enforcement. José was responsible for the enforcement of the IP protecting the world’s best-selling biological product, various multi-billion small molecule pharmaceutical products, and many other healthcare products and devices, as well as for defending these products against infringement claims from third-parties. He also formed a new department focused on counseling Abbott’s various business units regarding regulatory requirements of the FDA, European Medicines Agency and other international regulatory agencies. José also led Abbott’s litigation department, where he was responsible for providing pre-litigation and litigation advice regarding key issues facing healthcare companies, such as antitrust, healthcare compliance, fraud and abuse laws, contracts and financial laws. Before joining Intellia, he was the Chief Ethics and Compliance Officer at AbbVie responsible for its global compliance program.
José graduated from Boston College with a degree in economics, and received his J.D. from Harvard Law School.

Andrew Schiermeier has spent two decades as an executive in the biotech and pharmaceutical sectors, with experience ranging from managing operations for startups to directing the strategic expansion of global brands.
He is responsible for setting the strategic direction and oversight of all operations for eXtellia, which develops ex vivo applications of the CRISPR/Cas9 technology with an initial focus on immuno-oncology and autoimmune disorders.
Andrew joined Intellia in January 2017, having most recently served as SVP and Global Head of Merck KGaA’s Oncology Business, a global operation with revenues in excess of $1 billion. While at Merck, he was responsible for re-energizing the company’s oncology pipeline, continuing the growth and expanded indications of Erbitux®, and overseeing the development and launch of the world’s first commercialized blood-based biopsy. After successfully partnering the company’s anti-PDL1 antibody avelumab with Pfizer in 2014, he also held the position of General Manager for the Merck-Pfizer Immuno-Oncology Alliance.
Prior to Merck, Andrew served as chief operating officer of Aura Biosciences, a pre-clinical stage biotech startup in Cambridge, MA. He also held executive leadership positions at Medicine in Need Corp.; LantiBio, Inc.; and Paramount BioSciences.
Andrew holds several advanced degrees, including an International MBA from the College Des Ingenieurs in Paris; a Ph.D. in Applied Mathematics from Harvard University; and a Master of Science degree in Bio-Mechanical Engineering from Stanford University.

Jennifer Smoter brings more than 20 years’ experience in the global biotech biopharmaceutical, and healthcare industries to her role leading Intellia’s external affairs and communications. She is a recognized expert in corporate identity, brand, advocacy, stakeholder engagement and communications. Jennifer oversees communications, corporate marketing, government affairs, public affairs, patient access and stakeholder engagement.
Jennifer oversaw the global communications, patient advocacy and corporate marketing organizations for AbbVie, after leading communications for AbbVie’s successful separation from Abbott, the single largest transaction in NYSE history. AbbVie was named a Top 5 brand by FutureBrand in 2015 and a Top 20 brand in 2014. Jennifer previously held a number of senior-level communications roles in Abbott, including head of communications for the consumer-facing Nutrition business and head of Public Affairs for global pharmaceuticals.
Jennifer holds more than a dozen awards for public relations and brand campaigns and founded and led Amicus Communications & Brand Management, a network of senior-level communication and brand management consultants working in regulated industries.
Jennifer received her Bachelor of Arts Degree from Alverno College in Milwaukee, Wisconsin with focus areas of Philosophy, Communications and Social Sciences.

Perry Karsen brings decades of successful executive leadership and board experience to his role as Chairman of the Board of Intellia, a position he assumed in April 2016. He has served in senior executive positions in multi-national biopharmaceutical companies, has led start-up biotechnology companies, and is a member of the board of directors for both public and private biopharmaceutical companies. He also has been a board member and a member of the Executive Committee of the Biotechnology Innovation Organization (BIO) and the Alliance for Regenerative Medicine (ARM).

Perry served as the Chief Executive Officer of the Celgene Cellular Therapeutics division (CCT) of Celgene Corporation, a global biopharmaceutical company. Prior to being named CEO of CCT, he served for nearly a decade in other senior executive positions at the company, as Chief Operations Officer and Executive Vice President, and before that as Senior Vice President and Head of Worldwide Business Development. Perry was also President and Chief Executive Officer of Pearl Therapeutics, Inc., a privately held biotechnology company subsequently acquired by AstraZeneca plc.

Perry has held executive positions at Human Genome Sciences, Inc., a biopharmaceutical company subsequently acquired by GlaxoSmithKline; Bristol-Myers Squibb Co; Genentech, Inc., a member of the Roche Group; and Abbott Laboratories. He previously served as a general partner at Pequot Ventures, a venture capital firm.

Perry currently serves as Chairman of the Board of Directors for both OncoMed Pharmaceuticals and Jounce Therapeutics, and serves as a board member for Voyager Therapeutics. He also is a member of the Gladstone Foundation Board and the Sonoma Land Trust Board of Directors.

Perry earned a masters of management degree from Northwestern University’s Kellogg Graduate School of Management, and holds an M.A. in the teaching of biology from Duke University and a B.S. in biological sciences from the University of Illinois, Urbana-Champaign.

With a distinguished 30-year career as a top financial executive, Caroline Dorsa brings strong financial credentials and management expertise to Intellia’s Board of Directors, which she joined in 2015. In addition to her membership on Intellia’s board, she serves on the boards of directors for Biogen, Inc., where she chairs the audit committees, and Illumina, Inc. She is also on the board of trustees of several Goldman Sachs investment funds, such as the Goldman Sachs ETF Trust, the Goldman Sachs MLP and Energy Renaissance Fund and the Goldman Sachs MLP Income Opportunities Fund.
Caroline served as Executive Vice President and Chief Financial Officer of Public Service Enterprise Group, an integrated provider of regulated utility electric and gas distribution services, from April 2009 until her retirement in October 2015. Prior to that she served as Senior Vice President, Global Human Health, Strategy and Integration for Merck & Co. and Senior Vice President and CFO at Avaya, Inc., where she oversaw its leveraged buyout in 2007.
Caroline was honored in 2015 with the New Jersey Governor’s Jefferson Award for Public Service for her support of youth development in the state. She holds an MBA from Columbia University and earned her B.A. at Colgate University.

Jean-François Formela focuses on new advances in biology and drug discovery technologies as well as novel therapeutics.
He is chair of the board of IFM Therapeutics and serves on the boards of F-star, Kyn Therapeutics, Spero Therapeutics, and Translate Bio (formerly RaNA Therapeutics), which he co-founded.
Jean-François has been involved in the formation of companies such as Adnexus (acquired by BMS), ArQule (NASDAQ: ARQL), Arteaus Therapeutics (acquired by Eli Lilly), Cellzome (acquired by GSK), deCODE (NASDAQ: DCGN, acquired by Amgen), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM, acquired by Fresenius Medical) and SGX Pharmaceuticals (NASDAQ: SGXP, acquired by Eli Lilly). He also was an investor in Achillion (NASDAQ: ACHN), Annovation Biopharma (acquired by The Medicines Company), CoStim Pharmaceuticals (acquired by Novartis) and Horizon Pharma (NASDAQ: HZNP) as well as a board member of Biochem Pharma (NASDAQ: BCHE, acquired by Shire) and Novexel (acquired by AstraZeneca).
Jean-François joined Atlas Venture in 1993 to build the U.S. life sciences franchise. Prior to joining Atlas, Jean-François worked at Schering-Plough, where he directed U.S. Phase IV studies in all therapeutic areas. Before that, he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon. Jean-François began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris.
Jean-François is a member of the Massachusetts General Hospital Research Advisory Council and a former trustee of the Boston Institute of Contemporary Art.
He received his M.D. from Paris University School of Medicine, and his M.B.A. from Columbia University.

After a 30-year career in pharmaceutical R&D, John Leonard retired from his position as Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie in 2013. Inspired by the opportunity to work with a new therapeutic modality and form a new company, he returned to his life’s passion and joined the Intellia team to direct the research and development effort to make CRISPR/Cas9 technology into a therapeutic reality.
John is among the leading R&D executives who have led breakthrough medicines through their discovery, development and launch into blockbuster drugs. While serving as the Global Head of Pharmaceutical R&D at Abbott Laboratories, John oversaw the development of numerous novel therapeutics. His ground-breaking work with HIV protease inhibitors Norvir® and Kaletra® led to new treatment paradigms for AIDS, his years of work with Humira® made it the all-time top-selling drug worldwide, and he led significant growth of the R&D pipeline at Abbott and Abbvie. John’s teams were twice recognized with the prestigious Prix Galien Award for excellence in pharmaceutical research.
In addition to serving on the Board of Directors of Intellia, John serves on the Board of Directors of QuintilesIMS (NYSE:Q) and Chimerix (NASDAQ:CMRX). He received his M.D. from the Johns Hopkins University School of Medicine and completed his residency in Internal Medicine at Stanford University School of Medicine followed by a fellowship at the National Institutes of Health.

Frank Verwiel brings more than 25 years of strategic, operational and international experience in the biotech and pharmaceutical industry to Intellia’s Board of Directors. Frank currently serves as chairman of the board of directors of ObsEva SA, a biopharmaceutical company focused on women’s reproductive health. He also holds membership and committee chair positions on the boards of AveXis, Inc. (NASDAQ: AVXS), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Bavarian Nordic A/S (CPH: BAVA). Previously, he served on the board of directors of the Biotechnology Industry Organization.
Frank possesses significant biotech and pharmaceutical experience, having been the President and CEO of Aptalis Pharma Inc., prior to its acquisition in 2014 by Forest Laboratories. Frank also led the global hypertension franchise at Merck & Co. and served as the general manager of Merck Sharpe Dohme’s operations in the Netherlands and held numerous leadership positions in the commercial organization at Servier Laboratories.
Frank received a doctorate in medicine from Erasmus University in Rotterdam, Netherlands. He received his MBA from the Institut Européen d’Administration des Affaires (INSEAD) in Fontainebleau, France.

Rodolphe Barrangou is the Todd R. Kaenhammer Distinguished Professor in Probiotics Research in the Department of Food, Bioprocessing and Nutrition Sciences at North Carolina State University. His lab focuses on the biology and genetics of CRISPR-Cas immune systems in bacteria. Until July 2016, he also served as the Chairman of the Board of Directors of Caribou Biosciences. Rodolphe was previously a Director of Research and Development at DuPont and Danisco. While with Danisco, he was part of the team that initially established the adaptive immune function of CRISPR. Rodolphe holds nine patents related to CRISPR and has published more than 100 papers and seven book chapters in the field. For his work as a pioneer in CRISPR-Cas9, he has been awarded the distinguished 2017 National Academy of Sciences Award in Molecular Biology, the 2016 Canada Gairdner International Award and the 2016 Warren Alpert Foundation Prize. In 2018, he was elected into the National Academy of Sciences (NAS), one of the world’s most important and influential scientific societies. Rodolphe received his Ph.D. in Functional Genomics from North Carolina State University and an MBA from the University of Wisconsin, Madison.

Nessan Bermingham is a venture partner at Atlas Venture, where he is involved with the formation and leadership of groundbreaking new biotechnology companies as part of the Atlas platform. He has more than 15 years of experience in investments in life sciences, including small molecules, biologics, medical devices and diagnostics companies through private, public and secondary markets.

Most recently, Nessan was the first founder and CEO of Intellia. His vision and drive made Intellia “one of the top 10 biotech start-ups in 2014,” a “Fierce 15 biotech company,” and one of the first CRISPR/Cas9 companies to complete an initial public offering.

As a partner at Atlas Venture and Omega Funds, and founding partner of Bio Equity Capital, he successfully managed multiple investments including financing, licensing, M&A and IPOs across the United States and Europe. In his career, Nessan has co-founded a number of healthcare and biotech startup companies, and was previously the CEO of Tal Medical, a medical device company spun out of Harvard Medical School.

Nessan served on Intellia’s Board of Directors, the Board of Directors for the Alliance for Regenerative Medicine. Previously, he was on the Board of Directors for the Alliance for Regenerative Medicine, on the Advisory Board of the California Institute for Regenerative Medicine and sat on the independent Advisory Board of Merck Serono. Nessan served as program co-chair of the 2018 Biotechnology Innovation Organization (BIO) International Convention.

He received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine.

Jennifer Doudna is redefining what’s possible with genetic engineering. As an internationally renowned and award-winning professor of Chemistry and Molecular and Cell Biology at U.C. Berkeley, in 2012, Dr. Doudna and her colleagues uncovered CRISPR-Cas9 – a simple way of editing the DNA of any organism using a common protein found in bacteria. Doudna’s research with her collaborators has opened the floodgates of possibility for non-human and human applications including assisting researchers in the fight against HIV, sickle cell anemia and cystic fibrosis.
Today, Jennifer is widely recognized as a leading expert on RNA-protein biochemistry, CRISPR biology, and genome engineering. In addition to her position as a Howard Hughes Medical Institute investigator and a faculty affiliate of the Lawrence Berkeley National Lab, Doudna is Executive Director of the Innovative Genomics Institute and a member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors and the American Academy of Arts and Sciences, and she is a Foreign Associate of the Royal Society.

Rachel Haurwitz is the CEO, President and co-founder of Caribou Biosciences, as well as a co-founder of Intellia. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-derived technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. She has a research background in CRISPR biology. In 2017, she was named by the MIT Tech Review as one of the “35 Innovators Under 35” and in 2016, she was named by Fortune to the “40 Under 40” Business Leaders Under 40 list. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.

Luciano Marraffini is an Assistant Professor of Bacteriology at Rockefeller University. Luciano’s laboratory investigates the underlying molecular mechanisms of CRISPR immunity, and seeks to understand this natural pathway to develop new technologies. He is a 2016 Howard Hughes Medical Institute-Simons Faculty Scholar, 2012 Rita Allen Foundation Scholar and 2011 Searle Scholar, as well as the recipient of the 2016 Albany Medical Center Prize in Medicine and Biomedical Research, the 2016 Earl and Thressa Stadtman Scholar Award and the 2015 Hans Sigrist Prize. Luciano received his Ph.D. from the University of Chicago where he studied bacterial pathogenesis, and completed his postdoctoral fellowship at Northwestern University.

Andy May is the Senior Director of Genome Engineering at the Chan Zuckerberg Biohub, a non-profit medical research institute. Before joining the Chan Zuckerberg Biohub, Andy was the Chief Scientific Officer at Caribou Biosciences, where he lead the development of the CRISPR/Cas9 technology platform. He has a strong background developing technologies and bringing innovative products from concept to commercialization. Prior to Caribou, Andy led development teams at Fluidigm Corporation that pioneered efforts in single-cell genomics, high-throughput amplicon sequencing and structural proteomics. Andy received a B.A. in Chemistry and a D.Phil. in Molecular Biophysics from the University of Oxford and was a Wellcome Trust International Postdoctoral Fellow at Stanford University.

Derrick Rossi is an Associate Professor in the Stem Cell and Regenerative Biology Department at Harvard University, an Associate Professor in the Department of Pediatrics at Harvard Medical School, and an Investigator in the Program in Cellular and Molecular Medicine at Boston Children’s Hospital, where he holds an endowed Chair. Derrick also is a faculty member of the Harvard Stem Cell Institute. Derrick earned his B.Sc. and M.Sc. degrees from the University of Toronto, Canada, and his Ph.D. from the University of Helsinki, Finland. Derrick is a hematopoietic stem cell expert who has made multiple important discoveries relevant to human health. In 2010, Derrick’s lab discovered how to use synthetic mRNA to reprogram stem cell fate and function opening the field of mRNA therapeutics. His lab was the first to publish on using CRISPR/Cas9 to engineer blood forming stem cells that are resistant to HIV infection. Derrick has co-founded several companies, including Moderna Therapeutics in 2010 and Magenta Therapeutics in 2016. Derrick was named one of Time’s 100 Most Influential People in 2011.

Erik Sontheimer is a Professor in the RNA Therapeutics Institute at the University of Massachusetts Medical School. Erik’s lab studies the roles of RNA molecules in gene regulation and their applications in genome engineering. While a Professor at Northwestern University, Erik helped unravel the mechanism of CRISPR-mediated immunity in bacteria. He has been honored with the Burroughs Wellcome Fund New Investigator Award in the Pharmacological Sciences and a National Science Foundation CAREER Award. In 2016, he was elected a Fellow of the American Academy of Microbiology. Erik received his Ph.D. in Molecular Biophysics and Biochemistry from Yale University and completed his postdoctoral fellowship at the University of Chicago.